3P Biopharmaceuticals awards prize for the best Final Degree Project in Pharmacy at the University of Navarra

The award forms part of an agreement between 3P and the Faculty of Pharmacy at the University of Navarra promoting digital transformation and professional training within the pharmaceutical industry.

 3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of biological products, recently awarded the best Final Project Degree (FPD) of Pharmacy.

The award forms part of an agreement between 3P and the Faculty of Pharmacy at the University of Navarra promoting digital transformation and professional training within the pharmaceutical industry. At the same time, encouraging research in technologies, and the production of new medicines, particularly in biotechnologies.

3P Biopharmaceuticals awards its first prize for the best Final Degree Project in Pharmacy at the University of Navarra

The first winner of the 3P award is Ángela Covo, a Pharmacy degree student, for her experimental work on: “Overcoming T cell dysfunction in the acidic tumor microenvironment.” Ángela successfully achieved a grade of 9.32 and was awarded a prize of €300 and a diploma.

According to the CEO of 3P Biopharmaceuticals, Dámaso Molero, “It is an honor to be able to present the first 3P Biopharmaceuticals Award for the best Final Degree Project. All the graduating students have obtained very high grades and it tells us that we are training future professionals with a technical-scientific profile of the highest level who will add a lot of value to Navarra and the Spanish biopharmaceutical sector.

The agreement with 3P and the Pharmacy Faculty concentrates on new medicine and advanced therapies in R&D, including the development of biological drugs, cell and gene therapy, manufacturing and analytical technology, and dispensing technology. With the intention of manufacturing drugs that are safer and aimed at diseases that, until now, have no cure or with treatments without serious side effects.

In addition to the 3P Final Degree Project award, the collaboration between the two bodies delivers events, courses, seminars, and scientific meetings.

View the full press release here

Our dedicated team of specialists will be happy to discuss any of your CDMO supply chain needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.

Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals lands in the United States.

Published: 8th June 2023
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
Read more

3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.

Published: 2nd May 2023
The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.